

# THE PROTECTIVE ROLE OF METHANE IN MITOCHONDRIAL AND METABOLIC PATHWAYS OF ISCHEMIA/REPERFUSION- INDUCED CARDIAC DAMAGE

*By Dévid Kurszán Jász*

**THE PROTECTIVE ROLE OF METHANE IN  
MITOCHONDRIAL AND METABOLIC PATHWAYS OF  
ISCHEMIA/REPERFUSION-INDUCED CARDIAC DAMAGE**

**Doctoral (Ph.D.) dissertation**

**Dávid Kurszán Jász**

**Supervisor: Dr. Petra Hartmann**

**Szeged**

**2022**

**CONTENTS**

List of abbreviations .....	4
List of original papers relating to the subject of the thesis .....	6
<b>1. INTRODUCTION</b> .....	7
1.1. Ischemia-reperfusion (I/R) .....	7
1.2. Mechanism of I/R-induced mitochondrial dysfunction .....	8
1.3 Cardiac transplantation .....	8
1.4. Chemical properties and bioactivity of methane (CH <sub>4</sub> ) .....	9
1.4.1. The effect of CH <sub>4</sub> on I/R injury .....	10
1.5. The role of mitochondria in I/R damage .....	10
<b>2. MAIN GOALS</b> .....	12
<b>3. MATERIALS AND METHODS</b> .....	13
3.1. Study I. Investigation of the effects of CH <sub>4</sub> -enrichment of preservation solution on heart grafts in an experimental transplantation setup .....	13
3.1.1. Production of CH <sub>4</sub> -enriched Custodiol (CS) .....	13
3.1.2. Experimental protocol .....	14
3.1.3. Rat model of heterotopic heart transplantation (HTX) .....	15
3.1.4. Hemodynamic measurements .....	16
3.1.5. Examination of mitochondrial function .....	16
3.1.6. Quantitative real-time PCR (qPCR) analysis .....	16
3.1.7. Biochemical assays .....	17
3.1.8. Histology and immunohistochemistry .....	18
3.1.9. Statistical analysis .....	18
3.2. Study II. <i>In vitro</i> effects of CH <sub>4</sub> during anoxic stress and evaluation of mitochondrial membrane potential changes .....	18
3.2.1. Isolation of cardiac mitochondria .....	19
3.2.2. Experimental protocol .....	19
3.2.3. Examination of mitochondrial functions .....	20
3.2.4. Mitochondrial H <sub>2</sub> O <sub>2</sub> production .....	20
3.2.5. Mitochondrial membrane potential .....	20
<b>4. RESULTS</b> .....	20
4.1. Results of Study I .....	20

4.1.1. Hemodynamic parameters of the transplanted grafts .....	20
4.1.2. Cardiac mitochondrial function.....	21
4.1.3. Myocardial ER stress- and apoptosis-associated gene expression .....	22
4.1.4. Oxidative stress markers described by biochemical assays .....	23
4.1.5. Laboratory parameters of myocardium-specific enzyme changes .....	24
4.1.6. Histology and immunohistochemistry .....	25
4.2. Results of Study 2.....	26
4.2.1. <i>In vitro</i> effects of CH <sub>4</sub> during anoxic stress and evaluation of mitochondrial membrane potential changes .....	26
4.2.2. Extramitochondrial Ca <sup>2+</sup> -induced membrane potential changes .....	27
5. DISCUSSION .....	29
5.1. Effects of CH <sub>4</sub> during cold ischemia and reperfusion of graft. ....	29
5.2. The role of mitochondria in I/R damage .....	31
6. SUMMARY OF NEW FINDINGS .....	36
7. ACKNOWLEDGMENTS .....	37
8. FUNDING STATEMENT .....	37
9. REFERENCES .....	37



## List of abbreviations

$^3\text{H}$	Tritium
A/R	Anoxia re-oxygenation
AIF	Apoptosis inducing factor
Akt	Protein kinase B
Ama	Antimycin A
ATP	Adenosine triphosphate
Bak	Bcl-2 homologous antagonist killer
Bax	Bcl-2 associated protein X
Bok	Bcl-2 related ovarian killer
Bcl-2	B-cell lymphoma protein-2
$\text{Ca}^{2+}$	Calcium ion
CBF	Coronary Blood Flow
CCCP	Carbonyl cyanide m-chlorophenyl hydrazine
$\text{CH}_4$	Methane
CHOP	CCAAT/enhancer binding protein homologous protein, same as Ddit3
CK	Creatine kinase
$\text{CO}_2$	Carbon-dioxide
CS	Hystidine-tryptophane-ketoglutarate, Custodiol
Ddit3	DNA damage-inducible transcript 3, same as CHOP
DIABLO	Direct Inhibitor of Apoptosis-Binding protein with LOw pI
ER	Endoplasmic reticulum
ETC	Electron transport chain
GSH	Reduced glutathione
GSK-3 $\beta$	Glycogen synthase kinase-3 $\beta$
GSSG	Oxidized glutathione disulfide
Hif1 $\alpha$	Hypoxia-inducible factor 1- $\alpha$
HRR	High-resolution respirometry
HTX	Heterotopic transplantation
Hsp	Heat shock protein
I/R	Ischemia-reperfusion
LDH	Lactate dehydrogenase
LV	Left ventricle

LVSP	Left ventricle systolic pressure
Mcl-1	Induced myeloid leukemia cell differentiation protein
MiRO5	Mitochondrial respiratory medium
MPO	Tissue myeloperoxidase
mPTP	Mitochondrial permeability transition pore
mRNA	Messenger RNA
Na <sup>+</sup>	Sodium ion
NADH	Nicotinamide adenine dinucleotide hydride
N <sub>2</sub>	Nitrogen
NO	Nitrogen monoxide
NO <sub>x</sub>	Tissue nitrite/nitrate level
Nrf2	Nuclear factor-erythroid2 p45-related factor 2
OxPhos	Oxidative phosphorylation capacity
PAS	Photoacoustic spectroscopy
PI3K	Phosphoinositide 3-kinase
qPCR	Quantitative real-time PCR
RET	Reverse electron transport
ROS	Reactive oxygen species
Rot	Rotenone
ROX	Residual oxygen consumption
Smac	Second mitochondria-derived activator of caspase
SERCA1	Sarco(endo)plasmic reticulum Ca <sup>2+</sup> ATPase
Succ	Succinate
URL	Upper reference limit
VLDLr	Very low-density lipoprotein receptor
XOR	Xanthine oxidoreductase

### List of original papers relating to the subject of the thesis

<sup>10</sup>  
**Jász DK**, Szilágyi ÁL, Tuboly E, Baráth B, Márton AR, Varga P, Varga G, Érces D, Mohácsi Á, Szabó A, Bozó R, Gömöri K, Görbe A, Boros M, Hartmann P. (2021). Reduction in hypoxia-reoxygenation-induced myocardial mitochondrial damage with exogenous methane. *J CELL MOL MED*, 25(11):5113-5123. doi: 10.1111/jcmm.16498. **IF.: 4.486**

<sup>3</sup>  
Benke K, **Jász DK**, Szilágyi ÁL, Baráth B, Tuboly E, Márton AR, Varga P, Mohácsi Á, Szabó A, Széll Z, Ruppert M, Radovits T, Szabó G, Merkely B, Hartmann P, Boros M. (2020). Methane supplementation improves graft function in experimental heart transplantation. *J HEART LUNG TRANSPLANT*, 40(3):183-192. doi: 10.1016/j.healun.2020.11.003. **IF.: 7.865**

**Cumulative IF of relating publications: 12.351**

### <sup>3</sup> <sup>3</sup> List of full papers not relating to the subject of the thesis

Hartmann P, Butt E, Fehér Á, Szilágyi ÁL, **Jász DK**, Balázs B, Bakonyi M, Berkó Sz, Erős G, Boros M, Horváth Gy, Varga E, Csányi E. (2018) Electroporation-enhanced transdermal drug delivery into the knee joint in a rat model of acute arthritis. *DRUG DES DEVEL THER*. 12: 1917-1930. doi: 10.2147/DDDT.S161703. **IF.: 4.162**

Horváth T, **Jász DK**, Baráth B, Poles MZ, Boros M, Hartmann P. (2020) Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation. *INT J MOL SCI*. 10;22(6):2816. doi: 10.3390/ijms22062816. **IF: 4.556**

Varga G, Ugocsai M, Hartmann P, Lajkó N, Molnár R, Szűcs S, **Jász DK**, Érces D, Ghyczy M, Tóth G, Boros M. (2018). Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without causing gastric side effects in a rat model of colitis. *INFLAMMOPHARMACOLOGY*. 26(1):261-271. doi: 10.1007/s10787-017-0354-z. **IF: 4.07**

Baráth B, **Jász DK**, Horváth T, Baráth Be, Maróti G, Strifler G, Varga G, Sándor L, Perényi D, Tallósy Sz, Donka T, Jávör P, Boros M, Hartmann P (2022). Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. *INT. J. MOL. SCI*. 23(9):5064, doi:10.3390/ijms23095064 **IF:5.924**

**Cumulative IF.: 31.063**

## 1. INTRODUCTION

### 1.1. Ischemia-reperfusion (I/R)

Cardiac muscle cell contraction is essential for maintaining the life-long need of blood flow in our body. This mechanism, however, requires loads of oxygen to work in proper way. Most common cardiac conditions (e.g. myocardial infarction, hypertrophy, etc.) involve ischemia (decrease in blood flow and consequential loss of tissue oxygen level) in their pathomechanism. Warm ischemic changes are built around the hypoxic intracellular milieu of cardiac muscle cells. Low intracellular oxygen level leads to mitochondrial deceleration, which causes adenosine-triphosphate (ATP) depletion [1]. Disability of mitochondrial electron transport chain (ETC) also causes upstream accumulation of succinate (Succ) and nicotinamide adenine dinucleotide hydride (NADH), which activates several alternative metabolic pathways. ATP loss of the cell also realized in the diminished function of primarily or secondarily ATP dependent ion channels [2]. These changes can hinder intracellular homeostasis and can cause adaptive changes to improve survival of cardiac muscle cells. Although ischemic condition can modify cellular physiology, it is important to prevent any further damage, which will occur when cardiac muscle cells are re-flooded with oxygen in the reperfusion period. Subsequent overdosage of oxygen and previously decelerated mitochondria together lead to production and release of reactive oxygen species (ROS). Cold ischemia is based on the same concept of hypoxia as warm ischemia, however, cold (4°C) environment decelerates metabolic rate of organs and tissues, so it can be used to induce effective protection against harmful metabolic changes. This characteristic makes cold ischemia suitable for organ preservation in transplantation. However, recent studies explored some other issues regarding cold ischemic injury [3]. Cold ischemia also exhausts energy stores while ATP production is decreased and anaerobic metabolic pathways activate. These changes result in development of acidic environment. Increased proton levels stimulate the type 1 Na<sup>+</sup>/H<sup>+</sup> antiporter, while the Na<sup>+</sup>/K<sup>+</sup> ATPase is also disturbed, which causes intracellular accumulation of Na<sup>+</sup>. Excessive load of Na<sup>+</sup> alters resting membrane potential of the cell, thus exchange of Na<sup>+</sup> and Ca<sup>2+</sup> become more significant which is characterized by the release of large amount of Ca<sup>2+</sup> in the cell. Intracellular Ca<sup>2+</sup> overload taken up by the mitochondria, but remained high intracellular Ca<sup>2+</sup> concentration further activates pro-apoptotic enzymes, such as phospholipases, calmodulin regulated proteases and endonucleases. Ca<sup>2+</sup> is also released from the endoplasmic reticulum (ER) as a consequence of cold environment. Ca<sup>2+</sup> not only provokes pro-apoptotic enzyme activity, it promotes

changes in gene expression via <sup>25</sup> the hypoxia-inducible factor 1-alpha (Hif-1 $\alpha$ ) pathway and even take part in the inner pathway of apoptosis by modulating mitochondrial death signals of Bax/Bcl2 system [4].

## 1.2. Mechanism of I/R-induced mitochondrial dysfunction

Avoiding mitochondria-connected damage of the graft should be considered as the main goal to improve organ preservation methods. Life of the cell is strongly attached to mitochondrial metabolism through mechanisms such as ATP synthesis, pro- and anti-apoptotic signaling pathways. I/R initiates organ dysfunction through intracellular hypoxic damage, in which the mitochondria are highly involved. This contributes to unsuccessful graft transplantation [5-7]. Absence of blood flow and consequential ischemia causes a relatively well-discovered metabolic shift into anaerobic glycolysis involving the reduction of electron transport through ETC. Hypoxia also inhibits the function of <sup>2</sup> succinate dehydrogenase (respiratory complex II), thus <sup>2</sup> leading to NADH and <sup>2</sup> succinate accumulation; which is considered as a metabolic marker of ischemia [8-10].

Under hypoxic condition, oxidative phosphorylation of the mitochondria produces lower amount of ATP. Low intracellular ATP levels decrease the function of Na<sup>+</sup>/K<sup>+</sup> ATPases, therefore resting membrane potential changes. This state can be characterized by elevated intracellular Ca<sup>2+</sup> levels due to the altered function of Na<sup>+</sup>/Ca<sup>2+</sup> transporter and increased Ca<sup>2+</sup> efflux from the ER and mitochondria. Accumulated intracellular Ca<sup>2+</sup> is proved to influence mitochondrial permeability, potentiating ROS production, <sup>9</sup> both of which are enhanced during reperfusion [9]. Reperfusion is characterized by subsequent oxygen overload. Therefore, the reaction of previously leaked electrons and highly accessible oxygen result in ROS accumulation through the impaired ETC. <sup>9</sup> ROS-mediated damage to ETC complexes leads to more pronounced ATP depletion, completing the vicious circle of I/R, eventually initiating <sup>2</sup> apoptosis [10]. Increased ROS disintegrates mitochondrial lipid membrane, which opens <sup>9</sup> mitochondrial permeability transition pores (mPTPs) promoting Ca<sup>2+</sup>-induced mitochondrial <sup>2</sup> swelling. Mediators of the intrinsic apoptotic pathway are released into the cytoplasm due to increased mitochondrial membrane permeability.

## 1.3 Cardiac transplantation

In practice, transplantation involves both warm ischemic (during the surgical process) and cold ischemic (during cold storage) injury in its pathomechanism. Therefore, reduction of

reperfusion damage to improve graft function and minimize secondary cytokine storm or graft rejection is a highly important clinical goal [11].

Transplantation is necessary in the treatment of end-stage organ failure according to several guidelines, however improving graft survival and providing patient safety is still in the focus of clinical sciences [12]. The necessity of allograft protection and procurement cannot be emphasized enough as these factors correlate to graft survival rate in the clinical practice. Nowadays, static cold storage is still the most applied method for organ preservation after surgical explantation [13]. Nevertheless, currently used techniques provide limited protection against transient anoxia or reperfusion-induced tissue damage, therefore, seeking for advanced methods to avoid cold storage-related organ dysfunction is highly researched [14].

#### 1.4. Chemical properties and bioactivity of methane (CH<sub>4</sub>)

CH<sub>4</sub> is a colorless, odorless, omnipresent gaseous molecule, while being inert at ambient temperature and pressure. In the upper layer of the atmosphere CH<sub>4</sub> plays a role in ozone formation by reacting with hydroxyl radicals, however, physico-chemical reactions of CH<sub>4</sub> in eukaryotic organisms are still not fully discovered [9]. Early studies described that intraarterially administered <sup>14</sup>C-labelled CH<sub>4</sub> transformed into [<sup>14</sup>C]CO<sub>2</sub> in sheep [15]. Later [<sup>14</sup>C]CO<sub>2</sub> transformation into bound <sup>3</sup>H and carbon was proved in mammalian liver tissue [16].

These results indicated further investigation to explore the biological role of endogenous CH<sub>4</sub> in several eukaryotic organisms (fungi, algae, plants and animals) and proofs are now available for the production of CH<sub>4</sub> as a result of aerobic metabolic processes [9, 17-19].

Exogenously administered CH<sub>4</sub> was also investigated by many research groups [20-22]. *In vivo* studies described the biological effects of CH<sub>4</sub> on intestinal peristalsis and motility parameters [23-25] and improved survival rate in hemorrhagic shock in rats [26]. CH<sub>4</sub>-enriched fluids are proved to be protective against the consequences of I/R-induced conditions: inhalation of normoxic air containing 2.5% CH<sub>4</sub> has anti-inflammatory effect in intestinal and liver I/R injury [22]. Further experimental data demonstrated anti-oxidative, anti-apoptotic, and anti-inflammatory effects of CH<sub>4</sub> inhalation or CH<sub>4</sub>-enriched fluid therapies in I/R and in sepsis. Most importantly, CH<sub>4</sub> administration reduced the sepsis-induced ER-stress in the kidney through the suppression of GRP78/ATF4/CHOP/caspase-12-mediated apoptotic pathway [27].

Potentially dangerous characteristics of (5-15% of CH<sub>4</sub> in gas mixture can be flammable and explosive) explain that dissolving CH<sub>4</sub> in fluids would insure more safety in terms of its



application. CH<sub>4</sub>-enriched fluids and treatments were investigated in multiple experimental designs, where CH<sub>4</sub> gas was perfused in different composition of physiological saline solution [5, 23, 25, 28-31]. Nevertheless, the effects of CH<sub>4</sub> in the settings of organ transplantation and the circumstances and conditions that ensure the best efficiency in transplantation solutions have not been described yet.

#### 1.4.1. The effect of CH<sub>4</sub> on I/R injury

Distribution of CH<sub>4</sub> is well-characterized *in vivo*. Due to its apolar property, CH<sub>4</sub> is capable of penetrating membranes and diffusing into mitochondria; therefore, the potential effect of CH<sub>4</sub> on mitochondrial respiration can also be highly emphasized. Mitochondria are intracellular organelles with bacterial origin, so it can play various physiological roles, such as energy supply, ROS formation, Ca<sup>2+</sup> homeostasis, and programmed cell death. Several studies have demonstrated that mitochondria can be influenced by exogenously administered CH<sub>4</sub> in I/R injury via potential non-specific physico-chemical alterations of phospholipid bilayer of biological membranes [5, 28]. Mitochondrial respiration and ETC can also be modified by CH<sub>4</sub> administration as loads of *in vivo* and *in vitro* studies have been investigated [5, 31, 32].

I/R injury affects the ETC, which is embedded in the inner layer of mitochondrial membrane. Studies proved that CH<sub>4</sub> restored mitochondrial functions by nuzzling the rigidity of ETC to endure more significant oxidative stress during reperfusion [5, 22]. Similar to other simple molecules, CH<sub>4</sub> is likely to exert site-specific action on mitochondrial proteins or protein complexes. It seems that complex IV (cytochrome c oxidase), one of the protein complexes of the mitochondrial ETC, may be responsible for the action of CH<sub>4</sub> [5].

Several studies suggested that CH<sub>4</sub> modulates the intrinsic pathway (also known as mitochondrial pathway) of apoptosis [5, 25, 26, 30-33]. While CH<sub>4</sub> proved to be an anti-apoptotic agent, the mechanism behind its effect is not properly understood. Studies demonstrated that apoptosis reducing effect of CH<sub>4</sub> was associated with the release of cytochrome c and regulation of Bcl-2 family proteins, the latter causing interplay between pro-apoptotic and anti-apoptotic proteins [5, 6, 28].

#### 1.5. The role of mitochondria in I/R damage

Mitochondria are intracellular organelles, which function mainly is to provide energy for cell metabolism in the form of ATP. Also, mitochondria take part in several biochemical pathways of cellular metabolism, such as  $\beta$ -oxidation of fatty acids, Krebs cycle and

alternative carbohydrate metabolic pathways. Although energy production through mitochondrial ETC is substantial in terms of the life of eukaryotic cells; however, oxidative phosphorylation of mitochondria can be responsible for only the metabolism of the cell but also its death. In response to noxious stimuli, mitochondrial proteins can emerge into the cytoplasm to play essential role in the apoptotic process [31, 34, 35]. These proteins include e.g. caspases and procaspases, adenylate kinase 2, apoptosis inducing factor (AIF) and even proteins of the respiratory chain, such as cytochrome c, Smac/Diablo (recently discovered caspase coactivator) and some heat shock proteins (Hsp10, Hsp60). Apoptotic activity of mitochondria and protein release into the cytoplasm as a pro-apoptotic signal may be regulated, triggered or blocked by mitochondrial proteins of the Bcl-2 family. They can be distributed into two classes: pro-apoptotic proteins (such as Bcl-2 associated X protein (Bax), Bak, and Bok) and anti-apoptotic Bcl-2 family proteins (such as Bcl-XL, Bcl-w, Mcl-1, A1, Bcl-Rambo, Bcl-L10, and Bcl-G). Primarily, Bcl-2 reduces cytochrome c release to develop its anti-apoptotic characteristics. In contrast, stress-induced activation of pro-apoptotic members of Bak or Bax leads to increased permeability of mitochondrial outer membrane and subsequent emission of intermembrane space proteins e.g. cytochrome c and procaspases. Cytochrome c is a small peptide loosely associated with the outer side of the inner mitochondrial membrane and physiologically carries electrons between complex III and IV to provide the sufficient function of ETC. Membrane damage provokes its release into the cytoplasm where it initiates caspase cascade-mediated apoptosome formation, thus leading to apoptosis [28].

Mitochondrial ETC can be the main character in developing reperfusion injury. Overcharging the ETC with oxygen in the reperfusion period leads excessive function of ATP synthase enzyme known as complex V. However, oxygen overload not only effects ATP synthesis, but also accelerates the electron transport, which is leading to electron leakage through different complexes. Leaked electrons can be redirected into the ETC, or can reduce  $\text{NAD}^+$  leading to NADH accumulation. Another possibility for decreasing the locally elevated electron levels is using the already high amount of oxygen in the system thus creating ROS which is the main cause of oxido-reductive stress during reperfusion. High ROS levels can generate the apoptotic milieu of the cell, which later can kill the cell internally. Increased amount of intracellular ROS can lead to DNA damage, formation of inflammasomes and apoptosomes, and can influence intracellular transport system, such as through the Golgi apparatus and ER or through the nucleus and cytosol.



## 2. MAIN GOALS

We hypothesized that addition of <sup>2</sup>CH<sub>4</sub> to a cold preservation solution modifies the I/R-damage of the graft (Study I).

- Therefore, we examined the effect of CH<sub>4</sub>-enrichment on the oxido-reductive and nitrosative stress pathways in the myocardium <sup>20</sup>in a rat model of isogenic heart transplantation.
- We also investigated the expression of ER stress and mitochondrial apoptosis markers as possible underlying mechanisms of the cytoprotective action of CH<sub>4</sub> enrichment.

As a next step, we hypothesized that CH<sub>4</sub> influences the extramitochondrial Ca<sup>2+</sup> streams, which play a major role in the ER–mitochondria interactions (Study II).

- For this purpose, <sup>29</sup>we investigated the effects of exogenous Ca<sup>2+</sup> on the membrane potential changes of isolated cardiac mitochondria.
- Finally, we aimed to explore the potential target site on ETC responsible for the mitochondrial effects of CH<sub>4</sub> by using selective substrates and inhibitors of the respiratory complexes.

### **3. MATERIALS AND METHODS**

#### **3.1. Study I. Investigation of the effects of CH<sub>4</sub>-enrichment of preservation solution on heart grafts in an experimental transplantation setup**

The experiments were carried out on male Lewis rats (250–350 g; Charles River, Germany) in accordance with EU Directive 2010/63 for the protection of animals used for scientific purposes and in compliance with criteria set down in the US National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The study was approved by the national competent authority of Hungary (ATET) under licence number PEI/001/2374-4/2015.

##### **3.1.1. Production of CH<sub>4</sub>-enriched Custodiol (CS)**

Commercially-available CS solution (Dr. Franz Köhler Chemie GmbH, Bensheim, Germany) was saturated with pure CH<sub>4</sub> (>99.9%) under 0.4 MPa for 4 h in a high-pressure vessel (Messer, Budapest, Hungary), as described previously [36]. The CH<sub>4</sub> concentration in the fluid phase was detected by gas chromatography, while the stability of the solution was checked by near-infrared laser-based photoacoustic spectroscopy (PAS). The solution containing  $6.57 \pm 0.27 \mu\text{mol/ml}$  CH<sub>4</sub> was freshly prepared and stored at 4°C before use.

##### **3.1.1.1. Gas chromatography**

The CH<sub>4</sub>-enriched products were analysed with an Agilent 4890 gas chromatograph using an Equity-1 column connected to a flame ionization detector. HP Chemstation software was used for data evaluation. CH<sub>4</sub> calibration was performed with the multi-point syringe technique, which included the low range area. 15  $\mu\text{l}$  aliquots of CS solution were added to 2 ml gas-tight vials, which were previously degassed in an ultrasonic bath for 15 min. 50  $\mu\text{l}$  gas samples (controls or graft-exposed) were injected into the gas chromatograph three times in a row. The average CH<sub>4</sub> concentration in the fluid phase was  $6.57 \pm 0.27 \mu\text{mol/ml}$ .

##### **3.1.1.2. Photoacoustic spectroscopy (PAS) measurements**


The stability of dissolved CH<sub>4</sub> concentration in the CS solution was determined by PAS, a special mode of spectroscopy which measures optical absorption indirectly via the conversion of absorbed light energy into acoustic waves [37]. The set-up allows for dynamic, on-line measurements of CH<sub>4</sub> concentrations with a minimum detectable concentration of 0.25 ppm. The CH<sub>4</sub> measurements were performed in duplicates over a period of 120 min at 4°C. After

30', 60', 90' and 120 min equilibrium, the CH<sub>4</sub> concentration of the solution was measured in a gas-tight cuvette (containing 10 cm<sup>3</sup> of airspace and 10 cm<sup>3</sup> of liquid, respectively). The CH<sub>4</sub> concentration in the airspace of the cuvette is proportional to the CH<sub>4</sub> content dissolved in the liquid, and the content of dissolved gas bubbled through the liquid phase can be calculated based on the measured concentrations and the volume flow. The average CH<sub>4</sub> concentration in the fluid phase remained stable (105 ± 17.5 ppm/ml) during the 120-min investigations.

### **3.1.2. Experimental protocol**

Isogenic male Lewis to Lewis heterotopic transplantation (HTX) (n=36) was performed as described previously [6]. Briefly, after excision from the donors, the grafts were cold stored in a transplantation solution for 60 min (cold ischemia time), which was followed by HTX and a 60-min reperfusion period. At the end of the reperfusion, hemodynamic measurements were performed to evaluate early graft functions; thereafter, biopsies were taken from the left ventricle (LV) of the grafts for mitochondrial functional measurements and biochemical assays. Tissue myeloperoxidase (MPO) and xanthine oxidoreductase (XOR) activity, reduced glutathione (GSH) and oxidized glutathione disulfide (GSSG) ratio, and tissue nitrite/nitrate (NO<sub>x</sub>) level were determined. Blood samples for serum biomarkers of myocardial injury were taken from the vena cava at the end of the reperfusion period.

The animals were randomly allocated into three groups. In group 1 (control, n=12), donor rats underwent the same surgical procedure until the explantation, but the hearts were not subjected to cold storage and were not transplanted. In group 2 (n=12), the explanted grafts were stored in CS solution at 4°C during the 60-min cold ischaemic period, while the grafts were stored in CH<sub>4</sub>-enriched CS during the cold ischaemic period in group 3 (n=12) (Fig 1).



**Fig 1. Experimental protocol.** The heart grafts were explanted from the donors and stored for 60 min in preservation solution before HTX. 60 min after the start of reperfusion, hemodynamic measurements were performed in the recipients to evaluate early post-transplant graft function. Thereafter, samples were taken from the left ventricle for mitochondrial functional measurements, biochemical assays, qPCR analysis and histology. Hearts in the control group underwent the same surgical procedure as those of the donors but were not subjected to cold storage and transplantation. Grafts in the CS group were stored in cold (4°C) CS solution during the cold ischemia period; in the CS-CH<sub>4</sub> group, the protocol was identical, except that CH<sub>4</sub>-enriched CS solution was used.

### 3.1.3. Rat model of heterotopic heart transplantation (HTX)

HTX was performed in isogenic Lewis rats to avoid organ rejection. The technique has previously been described in detail [6]. Briefly, donor rats were anaesthetised with isoflurane, and heparin (25000 IU) was administered intravenously. A bilateral thoracotomy was performed to expose the heart and cold (4°C) cardioplegic CS solution (Dr. Franz Köhler Chemie GmbH, Bensheim, Germany, n=12) or CH<sub>4</sub>-enriched CS (CS-CH<sub>4</sub>, n=12) was infused into the coronaries via the aorta. The superior and inferior vena cava and the pulmonary veins were tied en masse with a suture, and the heart was excised with the aortic arch for the measurement of hemodynamics, including the coronary blood flow (CBF). After excision, the grafts were stored either in cold CS or CS-CH<sub>4</sub> for 60 min. Control hearts underwent the same surgical procedure but were not subjected to cold storage and transplantation (Control, n=12). The recipient rats were anaesthetised with isoflurane and

then heparinized (400 IU/kg iv), and body temperature was maintained at 37°C on a heating pad. Approximately 2-cm segments of the infrarenal aorta and the inferior vena cava were isolated and occluded with small-vessel forceps. The aorta and the pulmonary artery of the donor heart were anastomosed end to side to the abdominal aorta and the vena cava of the recipient, respectively. The duration of the implantation was standardized at 60 min (ischaemic period) to minimize time-related variability between experiments. After completion of the anastomoses, protamine (400 IU/kg iv) was administered to antagonize heparin effects. The occlusion was released, and the donor heart was reperfused with blood *in situ* for 60 min (see further as in Fig 1).

#### 3.1.4. Hemodynamic measurements

60 min after transplantation, a 3F latex balloon catheter (Edwards Lifesciences Corporation, Irvine, CA, USA) was introduced into the left ventricle (LV) via the apex to determine the maximal LV systolic pressure (LVSP), dP/dt<sub>max</sub> (maximal slope of systolic pressure increment) and dP/dt<sub>min</sub> by a Millar micromanometer (SPR-838, Millar Instruments) at different LV volumes (20-180  $\mu$ l). LV pressure-volume relationships were constructed from these data. The CBF of the graft was measured with an ultrasonic flow meter (Transonic Systems Inc., Ithaca, USA) mounted on the donor ascending aorta.

#### 3.1.5. Examination of mitochondrial function

The efficacy of the mitochondrial respiration was assessed from tissue samples homogenized in 3 ml mitochondrial respiration medium (MiRO5) by high-resolution respirometry (HRR, Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). Mitochondrial O<sub>2</sub> consumption (respiratory flux), complex II-linked baseline respiration (succinate-fuelled, in the presence of complex I inhibitor rotenone), oxidative phosphorylation capacity (OxPhos) and cytochrome c release (an indicator of inner mitochondrial membrane damage) were determined as described previously [5]. The respirometry data were normalized to the protein content determined by Lowry's method [5].

#### 3.1.6. Quantitative real-time PCR (qPCR) analysis

Myocardial mRNA expression was analysed by qPCR (Applied Biosystems, Foster City, CA, USA) for the following genes: caspase-3, caspase-9, DNA damage-inducible transcript 3 (Ddit3, also known as CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP)), Hif1 $\alpha$ , GSK-3 $\beta$  and very low-density lipoprotein receptor (VLDLr).

### 3.1.7. Biochemical assays

#### 3.1.7.1. Tissue xanthine oxidoreductase (XOR) activity<sup>6</sup>

Heart biopsies were homogenized in a phosphate buffer (pH 7.4) containing 50 mM Tris-HCl, 0.1 mM EDTA, 0.5 mM dithiotreitol, 1 mM phenylmethylsulfonyl fluoride, 10  $\mu\text{g ml}^{-1}$  soybean trypsin inhibitor and 10  $\mu\text{g ml}^{-1}$  leupeptin. The homogenate was centrifuged at 4°C for 20 min at 24 000 g and the supernatant was loaded into centrifugal concentrator tubes. The XOR activity was determined in the ultrafiltered supernatant by a fluorometric kinetic assay based on the conversion of pterine to isoxanthopterin in the presence (total XOR) or absence (XO activity) of the electron acceptor methylene blue [38].

#### 3.1.7.2. Reduced glutathione and oxidized glutathione disulfide (GSH/GSSG) ratio in heart homogenates<sup>2</sup>

The GSH/GSSG ratio was determined using a Fluorimetric Glutathione Assay Kit (Sigma Aldrich, Budapest, Hungary). The GSH content of the sample can be determined by quantifying the thiol concentration in biological samples by reacting with the thiol groups they contain. The adduct can be detected by fluorimetry at 478 nm. The GSSG content of the sample was calculated following the manufacturer's recommendations.<sup>3</sup>

#### 3.1.7.3. Tissue myeloperoxidase (MPO) activity<sup>7</sup>

The MPO activity was measured in biopsies using a method developed by Kuebler et al [39]. Briefly, the tissue was homogenized with Tris-HCl buffer (0.1 M, pH 7.4) containing 0.1 M polymethylsulfonyl fluoride to block tissue proteases, and then centrifuged at 4°C for 20 min at 24000 g. The MPO activity of the samples was measured at 450 nm (UV-1601 spectrophotometer; Shimadzu, Japan), and the data were referred to the protein content.

#### 3.1.7.4. Heart nitrite/nitrate (NOx) levels<sup>2</sup>

The levels of NOx, the stable end products of NO in the tissues were measured with the Griess reaction. This assay is based on the enzymatic reduction of nitrate to nitrite, which is then converted into a coloured azo compound, which is detected spectrophotometrically at 540 nm [40].

#### 3.1.7.5. Laboratory serum diagnostics

Serum myocardial biomarkers were measured using a chemiluminescence assay (Cobas 6000 automatic chemical analyser (Roche, Hungary). The upper reference limit (URL) for the

<sup>21</sup> creatine kinase (CK), CK-MB isoenzyme, lactate dehydrogenase (LDH) and Troponin T were 2000U/L, 2000 U/L, 1000U/L and 10000 ng/L, respectively.

### 3.1.8. Histology and immunohistochemistry

<sup>12</sup> The hearts were immersed and fixed in buffered paraformaldehyde solution (4%) embedded in paraffin, and 5- $\mu$ m thick sections were stained with haematoxylin and eosin (H&E). Immunohistochemical staining for the ER stress marker sarco(endo)plasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA1) was performed with SERCA1-specific antibody (#S1189, Sigma Aldrich, Budapest, Hungary) as previously described [41]. <sup>3</sup> Histological assessment was performed independently and blindly on coded slides by two investigators (K.D.J. and Z.S.) using a previously described 0–4-grade histological scoring system, representing a composite of number of damaged myocytes and number of foci of damage [42]. SERCA1 immunoreactivity was <sup>2</sup> determined using open-resource imaging software (ImageJ version 1.8) and expressed as a percentage of immunopositive cells quantified per field of view.

### <sup>3</sup> 3.1.9. Statistical analysis

The statistical analysis was performed with SigmaStat 13.0 statistical software (Jandel Corporation, San Rafael, CA, USA). Normal distribution was tested with the Kolmogorov–Smirnov test. In the case of a normal distribution, one-way ANOVA with Tukey's post-hoc test or the two-sample t-test was used. <sup>4</sup> Where data showed no normal distribution, ANOVA on rank was run. <sup>3</sup> Data are expressed as mean  $\pm$  SEM.  $P < 0.05$  was considered as statistically significant.

## 3.2. Study II. *In vitro* effects of $\text{CH}_4$ during anoxic stress and evaluation of mitochondrial membrane potential changes

<sup>3</sup> We examined the effects of dissolved  $\text{CH}_4$  on isolated mitochondria of rat cardiac muscle cells under anoxia re-oxygenation (A/R). <sup>3</sup>

The experimental protocol was in accordance with EU Directive 2010/63 for the protection of animals used for scientific purposes, and it was approved by the National Scientific Ethics Committee on Animal Experimentation (National Competent Authority) under license number V./148/2013. This study also complied with the criteria of the US National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.




### 3.2.1. Isolation of cardiac mitochondria

Adult Sprague Dawley rats were anesthetized to harvest the heart using sodium pentobarbital (45 mg/kg ip). The hearts were homogenized with a glass Potter homogenizer, and the mitochondria were isolated using Gnaiger's method [43]. Isolated mitochondria were suspended in 1 ml mitochondrial respiration medium (MiRO5) for respirometric analysis and were treated as follows: 2 h normoxia (95 % air and 5 % CO<sub>2</sub>) or anoxia (100 % N<sub>2</sub>) was followed by re-oxygenation (with or without CH<sub>4</sub>) for 30 min. At the end of the experiments, mitochondrial functions were tested.

### 3.2.2. Experimental protocol

Isolated cardiac mitochondria were treated as follows: anoxia was induced using 100% N<sub>2</sub> persufflation for 2 h into a 2 ml volume cuvette containing 1 ml respiratory medium and 1 ml airspace. Anoxia was followed by a re-oxygenation period (95% air and 5% CO<sub>2</sub>) with or without 2.2% CH<sub>4</sub> supplementation for 30 min (the A/R and A/R+CH<sub>4</sub> groups, respectively) (n=12–16). In the control groups, the mitochondria were kept in normoxic cuvettes (95% air and 5% CO<sub>2</sub>) with or without 2.2% CH<sub>4</sub> supplementation (the normoxia and normoxia+CH<sub>4</sub> groups, respectively). Then the mitochondria were subjected to HRR (Fig 2).



**Fig 2. Protocol for isolated mitochondria.** The mitochondria were isolated using Gnaiger's method and treated as follows: 2 h normoxia (95% air and 5% CO<sub>2</sub>) or anoxia (A) (100% N<sub>2</sub>) was followed by re-oxygenation (R) (with or without CH<sub>4</sub>) for 30 min. At the end of the experiments, mitochondrial function was tested. CH<sub>4</sub>: methane; CO<sub>2</sub>: carbon dioxide; N<sub>2</sub>:



nitrogen.

### 3.2.3. Examination of mitochondrial functions

HRR by Oxygraph-2k (Oroboros Instruments, Innsbruck, Austria) was used to examine the oxygen consumption of the isolated cardiac mitochondria under stimuli of different mitochondrial complexes, to determine mitochondrial hydrogen peroxide ( $H_2O_2$ ) production and to detect changes in mitochondrial membrane potential.

### 3.2.4. Mitochondrial $H_2O_2$ production

In this series, mitochondrial  $H_2O_2$  release as a marker of ROS (i.e. superoxide anion) production was monitored fluorimetrically with the Amplex Red/horseradish peroxidase system, whereby Amplex Red (non-fluorescent) is oxidised to Resorufin.  $H_2O_2$  production was calibrated with known amounts of  $H_2O_2$ . In this setup, ROS release was investigated by adding oxidizing substrates (10 mM glutamate, 5 mM malate, 20 mM S, 5 mM ADP) to the mitochondria. On isolated mitochondria, the reverse electron transport (RET)-initiated  $H_2O_2$  flux was measured when mitochondria were incubated with 20 mM Succ; it was then blocked by the addition of 1  $\mu$ M rotenone (Rot). The residual oxygen consumption was estimated after addition of 1  $\mu$ M antimycin A (Ama, an inhibitor of Complex III) to exclude the effects of oxidative side reactions. Then, free radical leak was also determined as the percentage of oxygen consumption diverted to the production of  $H_2O_2$  in State 3.

### 3.2.5. Mitochondrial membrane potential

Mitochondrial membrane potential was measured fluorimetrically using the fluorophore agent safranin. First, we added 1  $\mu$ M Rot, 10mM Succ and 1  $\mu$ M CCCP. Finally, residual oxygen consumption (ROX) was determined by adding 1  $\mu$ M Ama.


## 4. RESULTS

### 4.1. Results of Study 1.

#### 4.1.1. Hemodynamic parameters of the transplanted grafts

After transplantation, increasing LV balloon volumes ('preload') resulted in elevated LVSP and dP/dtmax, which were both significantly increased at the largest preload values in the CS-CH<sub>4</sub> group as compared to CS alone (Fig 3A–B). A similar change in diastolic function was noted at higher preload volumes, bringing about significantly elevated dP/dtmin values

( $p < 0.05$ ) compared to CS, reflecting better myocardial relaxation (Fig 3C). CBF was also significantly ( $p < 0.05$ ) higher after 60 min of reperfusion in CS-CH<sub>4</sub> storage as compared to the CS group (Fig 3D). There was no statistically significant difference in HR values within and between experimental groups (Fig 3E).




**Fig 3. Left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) changes.** A. Maximal slope of the systolic pressure increment (dP/dt<sub>max</sub>). B. Maximal left ventricular systolic pressure (LVSP). C. Diastolic pressure decrement (dP/dt<sub>min</sub>). D. Coronary blood flow (CBF) and E. Heart rate. White columns: CS group; black columns: CS-CH<sub>4</sub> group. Data are presented as means  $\pm$  SEM. # $P < 0.05$  vs CS (one-way ANOVA, Tukey's test).

#### 4.1.2. Cardiac mitochondrial function

Complex II-linked basal respiration was significantly higher in the CS-CH<sub>4</sub> grafts than in the CS group 60 min after reperfusion (data not shown). After adding saturating amounts of ADP, the OxPhos was significantly higher in the CS-CH<sub>4</sub> group (Fig 4C). Mitochondrial respiration in response to cytochrome c (Fig 4D) was tested to determine the ability of exogenous cytochrome c to replace the enzyme in the mitochondrial membrane. In comparison with the


CS group, the release of cytochrome c was significantly lower in the CS-CH<sub>4</sub> group.



**Fig 4. Oxygen consumption of cardiac mitochondria (pmol/s/mL<sup>-1</sup>).** The upper charts (A. and B.) demonstrate representative records of mitochondrial oxygen consumption of CS-stored (A.) or CS-CH<sub>4</sub>-stored (B.) samples measured by high-resolution respirometry. The blue line represents the instantaneous oxygen concentration in the respiration chamber, while the red line indicates the simultaneous oxygen consumption of the sample. C. and D. The lower right-hand chart shows OxPhos, and the lower left-hand chart demonstrates cytochrome c release data. Grey columns: control group; white columns: CS group; black columns: CS-CH<sub>4</sub> group. Individual data points are shown for each of the columns. Data are presented as means ± SEM. \*P<0.05 vs. CS; #P<0.05 vs. control (one-way ANOVA, Tukey's test).

#### 4.1.3. Myocardial ER stress- and apoptosis-associated gene expression


The relative mRNA expression for hypoxia- and ER stress-associated genes (Hif-1α, CHOP, GSK-3β and VLDLR) was significantly lower in the CS-CH<sub>4</sub> group (Fig 5). The expression of caspase-3 and caspase-9, and the pro-apoptotic Bax were not significantly decreased. However, the anti-apoptotic Bcl2 and the ratio of Bax/Bcl2 expression were significantly different in the CS-CH<sub>4</sub> group, thus indicating the relative dominance of anti-apoptotic pathways (Fig 5).



**Fig 5. Gene expression changes.** White columns: CS group; black columns: CS-CH<sub>4</sub> group. Individual data points are shown for each of the columns. Data are presented as means ± SEM. #P<0.05 vs. CS (one-way ANOVA, Tukey's test). Hif1α: hypoxia-inducible factor 1-alpha; VLDLr: very low-density lipoprotein receptor; CHOP: CCAAT/enhancer binding protein (C/EBP) homologous protein; GSK-3β: glycogen synthase kinase-3 beta. Bcl-2: B-cell lymphoma 2; Bax: bcl-2-like protein 4.

#### 4.1.4. Oxidative stress markers described by biochemical assays

XOR is a key enzyme in reperfusion-induced ROS production; in addition, it can catalyse the reduction of nitrates and nitrites to NO. XOR activity and tissue NO<sub>x</sub> levels were both significantly decreased when CS-CH<sub>4</sub> was applied during the cold ischemia period relative to the data for the CS group (Fig 6A-B). MPO is mostly produced by activated PMNs. While tissue MPO was significantly increased as compared to that of the control group, MPO activity was significantly reduced when CH<sub>4</sub>-CS was applied (Fig 6C). The GSH/GSSG ratio is one of the most important markers of oxido-reductive stress. This ratio was significantly decreased in the CS group; however, preservation of grafts in CS-CH<sub>4</sub> resulted in a sustained GSH/GSSG ratio (Fig 6D).



**Fig 6. Biochemical assays for oxido-reductive stress parameters.** A. Tissue xanthine oxidoreductase (XOR) activity. B. Nitrite/nitrate (NO<sub>2</sub>/NO<sub>3</sub>) levels. C. Myeloperoxidase (MPO) activity. D. Reduced glutathione and oxidized glutathione disulfide (GSH/GSSG) ratio. Grey columns: control group; white columns: CS group; black columns: CS-CH<sub>4</sub> group. Individual data points are shown for each of the columns. Data are presented as means ± SEM. \*P<0.05 vs. CS; #P<0.05 vs. control (one-way ANOVA, Tukey's test).

#### 4.1.5. Laboratory parameters of myocardium-specific enzyme changes


CH<sub>4</sub> admixture in the CS-CH<sub>4</sub> group resulted in significantly lower plasma LDH, CK, CK-MB and troponin T levels as compared to CS storage alone (Table 1).

	CK (U/L)	CK-MB (U/L)	LDH (U/L)	Troponin T (ng/L)
Control	503±57*	206±31*	358±79*	42±9 *
CS	2327±23 <sup>#</sup>	527±43 <sup>#</sup>	938±108 <sup>#</sup>	172±36 <sup>#</sup>
CS-CH <sub>4</sub>	1507±49* <sup>#</sup>	328±52* <sup>#</sup>	732±96* <sup>#</sup>	110±21* <sup>#</sup>

**Table 1. Myocardium-specific enzyme changes.** Data are presented as means ± SEM. \*P<0.05 vs. CS; #P<0.05 vs. control (one-way ANOVA, Tukey's post-hoc test).

#### 4.1.6. Histology and immunohistochemistry

H&E staining showed only a mild disorganisation of the myofibrils with loss of striations and a combination of waviness, contraction bands and disruption of plasma membranes of myocytes in the CS group as compared to the controls (Fig 7A-B). The architecture of cardiac myocytes was nearly normal in the CS-CH<sub>4</sub> storage group (Fig 7C). These changes were not significantly different from those in the CS group, thus indicating nearly equal potential for tissue protection (Fig 7D). The number of SERCA1 immunoreactive cardiac myocytes increased significantly in sections from CS-stored grafts as compared to the controls (Fig 7E-F). In contrast, the number of immunoreactive cells was significantly reduced in the CS-CH<sub>4</sub> group (Fig 7G-H).



**Fig 7. Histology and immunohistochemistry.** Haematoxylin and eosin staining (A-C) of heart sections. A. Control group. B. CS group. C. CS-CH<sub>4</sub> group. D. Histological grading of groups represents a composite of number of damaged myocytes and number of foci of damage.


SERCA1 immunostaining (E-G) of heart sections. E. Control group. F. CS group. G. CS-CH<sub>4</sub> group. H. SERCA1 immunoreactivity is demonstrated as percentage of immunopositive cells quantified per field of view. Individual data points are shown for each of the columns. Data are presented as means  $\pm$  SD. \*P<0.05 vs. CS; #P<0.05 vs. control (ANOVA on ranks, Tukey-Kramer). Magnification: 200x. Marker: 200  $\mu$ m.



## 4.2. Results of Study 2.

### 4.2.1. *In vitro* effects of CH<sub>4</sub> during anoxic stress and evaluation of mitochondrial membrane potential changes

Changes to mitochondrial membrane potential have been characterized by means of the potential-sensitive fluorophore safranin. Substrates of respiratory complexes induced a significant hyperpolarization in the mitochondrial membrane under normoxic conditions (Fig 8A). In contrast, hyperpolarization was eliminated in the A/R group. Substrate-induced changes in membrane potential were partially preserved by CH<sub>4</sub> supplementation (Fig 8A). CH<sub>4</sub> applied during the anoxic period lowered the amount of H<sub>2</sub>O<sub>2</sub> production in leak states (Fig 8B). In terms of oxygen consumption, we investigated complex I and succinate-semialdehyde dehydrogenase (complex II)-linked respiration separately. CH<sub>4</sub> significantly decreased the oxygen consumption of complex I, while it had no effect on complex II-linked respiration under normoxic conditions. In contrast, CH<sub>4</sub> treatment in the A/R+CH<sub>4</sub> group significantly improved the oxygen consumption of complex II compared to complex I (Fig 8C).



**Fig 8.** The effect of CH<sub>4</sub> on isolated cardiac mitochondria. The upper left-hand chart demonstrates representative records of mitochondrial membrane potential measured fluorimetrically by HRR. The continuous black line indicates changes in membrane potential; in parallel, the red line signifies the substrate-fuelled respiration. The upper right-hand chart

presents changes in membrane potential in the experimental groups. The A/R group is labelled with a red line, the A/R+CH<sub>4</sub> group with a black line, and the normoxia and normoxia+CH<sub>4</sub> groups with pale and dark grey lines, respectively. The lower left-hand chart shows complex I and II-driven mitochondrial oxygen consumption. The lower right-hand chart demonstrates H<sub>2</sub>O<sub>2</sub> production in the case of RET.


#### 4.2.2. Extramitochondrial Ca<sup>2+</sup> -induced membrane potential changes

Membrane potential changes evoked by extramitochondrial Ca<sup>2+</sup> in normoxic and anoxic environment was assessed in isolated cardiac mitochondria using a blue fluorescence sensor (excitation 465 nm; gain for sensor: 1000 and polarization voltage: 500 mV) on a high-resolution fluorepirometer. After the four-step titration of safranin, 100 µl of samples were loaded into the chambers. Then, mitochondria were treated with 1 µl of 0.5 µM Rot and 20 µl of 10 mM Succ. The responsiveness of the fluorescent dye was monitored by exogenous 20 µl of 20mM CaCl<sub>2</sub> in three-step titration until reaching a plateau. The Ca<sup>2+</sup> signal was eliminated with the addition of 1 µl of 1 µM Ama. Ca<sup>2+</sup>-related changes were expressed as the rate of changes in fluorescent signal and average resting fluorescence.

In response to anoxia the extent of hyperpolarization was less prominent compared to normoxic group. This was most probably due to the non-selective Ca<sup>2+</sup> efflux through mPTPs. However, CH<sub>4</sub> treatment resulted in significantly lower Ca<sup>2+</sup> efflux. These results are in accordance with the membrane potential measurements where incubation of the mitochondria with 2.2% CH<sub>4</sub> maintained the hyperpolarization. Interestingly, CH<sub>4</sub> treatment in the normoxia group caused Ca<sup>2+</sup> efflux to show no reactivity to substrates also seen in membrane potential measurements.

Of note, these results are preliminary because this method was originally developed to measure extramitochondrial Ca<sup>2+</sup> movement on liver mitochondria. The magnitude of Ca<sup>2+</sup> currents may be different in cardiac mitochondria; therefore, our method requires further validation.





**Fig 9.  $\text{Ca}^{2+}$  -induced membrane potential changes.** The A/R group is labelled with a red line, the A/R+CH<sub>4</sub> group with a black line, and the normoxia and normoxia+CH<sub>4</sub> groups with pale and dark grey lines. Data are presented as means  $\pm$  SEM. #P<0.05 vs. normoxia, \*P<0.05 vs. AR; (one-way ANOVA, Tukey's test).

## 5. DISCUSSION


### 5.1. Effects of CH<sub>4</sub> during cold ischemia and reperfusion of graft.

The CH<sub>4</sub> supplementation of the transplantation solution improved structures and functions in experimental HTX. The hemodynamic efficacy of CS-CH<sub>4</sub> storage was evidenced by increased LVSP, cardiac contractility and coronary circulation, as compared to CS-treated grafts. The sum of biochemical data showed that the CH<sub>4</sub>-containing Custodiol solution effectively reduced the degree of oxido-reductive stress in myocardial samples and significantly influenced several components of ER stress—mitochondria-related pro-apoptotic signaling pathways. In addition, high-resolution respirometry confirmed that CH<sub>4</sub> supplementation preserved the respiratory mechanism of cardiac mitochondria during cold storage. These pathways together may have contributed to improved structures and functions in this heart transplantation model.

Myocardium has particularly poor tolerance to prolonged ischemia, and the issue of preservation is a major concern in transplantation. CS solution is generally used in clinical practice; therefore, it is an appropriate testbed for alternative options [44]. Several gas mediators, such as NO, carbon monoxide (CO) and hydrogen sulphide (H<sub>2</sub>S) have already been tried as additives to solutions in transplantation models, assuming that a potential efficacy could be related to their tendency to react with biologically important molecules [45, 46]. In contrast, CH<sub>4</sub> is non-toxic *in vivo*; considered to be a simple asphyxiant, which means that hypoxia might occur when an increasing concentration of CH<sub>4</sub> displaces inhaled air in a restricted area and the concentration of oxygen is reduced [24]. Nevertheless, there are pertinent data which demonstrate that CH<sub>4</sub> can modulate NO-, CO- and H<sub>2</sub>S-linked reactions in living systems [47, 48]. In addition, higher concentrations of exogenous CH<sub>4</sub> can lead to direct anti-cytokine effects via master switches, such as Nrf2/Keap1 or NF-κB, and anti-inflammatory responses in experimental settings [5, 22, 29, 36]. In the case of myocardial I/R, treatment with CH<sub>4</sub>-enriched saline significantly ameliorated the sequelae of pro-inflammatory activation (evidenced by reduced TNF-α, IL-1β, MPO activity and oxidative DNA damage) and maintained satisfactory cardiac function four weeks after infarction [29]. Despite the wide range of research to map the biological effects, the role of CH<sub>4</sub> in cold ischemia or organ transplantation settings has not yet been investigated. Therefore, we manufactured a CH<sub>4</sub>-saturated CS solution according to reported protocols and in a concentration range, which demonstrated efficacy in I/R studies *in vivo* [36]. Many details of the mechanism are still unknown, but we have shown that this approach affected many

1 aspects of mitochondrial physiology during cold ischemia and after reperfusion, perhaps through an indirect influence on  $\text{Ca}^{2+}$  homeostasis [29, 36]. During circulatory arrest, depletion of mitochondrial substrates is a major contributor to  $\text{Ca}^{2+}$  influx-mediated membrane dysfunctions. As a result of  $\text{CH}_4$  enrichment, the mitochondria were more responsive to ADP utilization, which contributed to the maintenance of OxPhos. Furthermore, cytochrome c release, a sign of mitochondrial inner membrane injury, was also reduced (Fig 10).

The process of cold ischemia-induced cellular damage with the dual contribution of ER and mitochondria is relatively well characterized. Hypoxic conditions trigger changes in cytoplasmic resting potential and, through the activation of ER-mediated  $\text{Ca}^{2+}$  transport, increase the expression of Hif1 $\alpha$ , one of the key initial factors in the cascade of events, which will finally lead to cell apoptosis or necrosis [49-52]. More directly, as a consequence of Hif1 $\alpha$  expression, mRNA expression of VLDLr and the pro-apoptotic transcription factor CHOP are also increased, and by the end of this process, CHOP upregulates Bim mRNA expression and activates Bax protein to translocate from the cytosol to the mitochondria [49, 53]. Our results demonstrate that cold ischemia and graft storage activated all these participants, starting from higher SERCA1 protein levels reflecting an increased  $\text{Ca}^{2+}$  pump function in the ER and elevated Hif1 $\alpha$  expression in cardiomyocytes. In addition, higher intracellular  $\text{Ca}^{2+}$  can activate GSK-3 $\beta$ , the pro-apoptotic factor in the intrinsic mitochondrial apoptotic pathway [54]. These mitochondrial changes raise the expression of Bax protein and its activation, while modified pro-apoptotic Bax and anti-apoptotic Bcl2 levels lead to further pro-apoptotic events, such as cytochrome c release from the mitochondrial membrane. In our study, 1 CS- $\text{CH}_4$  storage did not influence the caspase enzyme system, but the Bax/Bcl2 ratio and the reduced cytochrome c release suggest that the intrinsic mitochondrial pathway of apoptosis was affected. More importantly, if the preservation solution was supplemented with  $\text{CH}_4$ , the expression of individual genes in the proposed signaling pathway was also reduced (Fig 10).



**Fig 10. Proposed effects of CH<sub>4</sub> supplementation on cold ischemia-induced intracellular changes.** Phospholipid membranes of the ER and the mitochondrion are possible targets. In the presence of a saturating amount of CH<sub>4</sub>, the expression of genes downstream of HIF1α decreases, affecting the mitochondrial pathway of apoptosis by lowering the Bax/Bcl2 ratio, thus creating an anti-apoptotic milieu for cardiac muscle cells.

In conclusion, our study has demonstrated that CH<sub>4</sub> enrichment of CS solution results in increased graft protection during cold ischemia and isogenic HTX in rats. Oxido-reductive imbalance is an inevitable consequence of *ex vivo* periods and a basis for a cascade of pro-inflammatory events following re-oxygenation. Based on the totality of data, it seems that CH<sub>4</sub> supplementation conferred increased efficacy on CS to reduce signs of nitroxidative stress as shown by the maintained GSH/GSSG ratio, reduced MPO and XOR activity, and lower NOx level in the reperfused myocardium.

The underlying mechanism is attributed at least partly to an influence of CH<sub>4</sub> on myocardial ER stress and its link to mitochondrial structural and functional reactions. CH<sub>4</sub> enrichment is a simple and effective option for static organ preservation and also seems feasible for dynamic graft storage. Future research should particularly seek to answer the question of whether this approach confers long-term protection in immunologically challenged situations.

## 5.2. The role of mitochondria in I/R damage

Expected mitochondrial effects of CH<sub>4</sub> have been characterized by HRR, and we have shown that the administration of CH<sub>4</sub> promotes mitochondrial protective effects on ETC and

apoptosis. Of importance, CH<sub>4</sub> preserved mitochondrial membrane potential (a marker of the integrity of the inner mitochondrial membrane) and several study shows decreased cytochrome c release (a sign of the integrity of the outer mitochondrial membrane) as well [4, 55].

Excessive oxidative stress is a major component of I/R, and the mitochondrial ETC is a dominant source of ROS generation. Likewise, the majority of superoxide production is linked to complex I early in reperfusion [56-59]. The concept of using reversible complex I inhibitors for ischemic preconditioning or as a pre-treatment to limit ROS generation and cardiac I/R injury has been demonstrated by several authors [60, 61]. Rotenone, an irreversible inhibitor of electron transport at the so-called ubiquinone (Q)-binding site, has been demonstrated to exert cardioprotection by decreasing RET in the early phase of reperfusion [58]. It should be added that two sites for superoxide production have recently been explored on respiratory complex I, the Q-binding and flavin sites, respectively [59]. The superoxide production at the flavin site is linked to the forward electron transport, and its rate depends on the reduction state of the matrix NAD pool. More importantly, the Q-binding site produces superoxide at much higher rates than the flavin site, driven by RET from complex II into complex I during the reperfusion [10].


In our model of cardiac I/R injury, we tracked mitochondrial ROS with HRR by using the fluorescent dye Amplex Red, while side by side analysis of mitochondrial membrane potential was occurred with potential-sensitive fluorescence dye safranin. Respiratory activity of complex I remained stunned in the re-oxygenation phase being interrelated with the overwhelming ROS production. CH<sub>4</sub> decreased the complex I-linked respiration in both control and ischemia-damaged mitochondria, but there were no changes in the presence of Rot, an irreversible complex I inhibitor, which suggests that CH<sub>4</sub> treatment reduced ROS generation via a partial blockade of electron transport in complex I.

In isolated cardiac mitochondria, the underlying mechanism of RET is the accumulation of Succ during ischemia and its subsequent rapid oxidation at reoxygenation in the presence of a high membrane potential [62]. However, recent discoveries have demonstrated that the difference between cold and warm ischemic injuries lies in the miscellaneous distribution of metabolic changes [4]. Our results suggest that the active site of CH<sub>4</sub> is similar to Rot, distal to the flavin site, since it enhances mitochondrial ROS generation when the electrons enter complex I from NADH while supporting the idea of NADH accumulation is a key issue in re-oxygenation injury. CH<sub>4</sub> also inhibits ROS generation by RET from complex II.

Large membrane potential is a prerequisite to drive the electrons against the gradient of redox potentials from complex II into complex I. It has been demonstrated in isolated mitochondria that only a 5% reduction in mitochondrial membrane potential will reduce peroxide production by 95% [63]. Any manipulation of the RET pathway could potentially influence the end outcome of ROS production, even by lowering the driving hyperpolarization of the mitochondrial membrane potential. Membrane potential also can be influenced by excessive  $\text{Ca}^{2+}$  stream occurring throughout the process of adapting to hypoxic conditions. Applied HRR protocols of our study can measure membrane potential changes in isolated mitochondria and simultaneously can describe  $\text{Ca}^{2+}$  flow through the outer mitochondrial membrane. Addition of normoxic  $\text{CH}_4$  slightly reduced the substrate-induced hyperpolarization in control mitochondria, in contrast to the preservative effect seen in the case of the anoxia-damaged membrane, while it decreased the  $\text{Ca}^{2+}$  flow from mitochondria. The difference between cold and warm ischemia, is that warm ischemia involves metabolic changes such as Succ accumulation, which further decreases the RET and subsequent ROS production, while during cold ischemia, mitochondrial adaptation can lower cytoplasmic  $\text{Ca}^{2+}$  levels, thus protecting the cell against hypoxic danger and apoptotic signals.

The role of complex I and complex II in the post-ischemic cardiac mitochondrial respiration was addressed in more detail. As a result of  $\text{CH}_4$  treatment, respiration was inhibited when glutamate + malate was used as a complex I substrate but not with Succ as a complex II substrate. This finding suggested that the addition of  $\text{CH}_4$  resulted in a decreased electron flux through complex I but did not alter the Succ oxidation through complex II. Based on these findings, the drop in net ROS production from mitochondria with preserved Succ oxidation in the presence of  $\text{CH}_4$  is most likely directly related to the inhibition of complex I. However,  $\text{CH}_4$  appears to provide a blockade of electron transport in complex I in contrast to a complete blockade of oxidative metabolism during reoxygenation (Fig 11).






**Fig 11. The effects of CH<sub>4</sub> on complex I.** The mechanism of protection likely included a blockade of the electron transport in complex I and decreased ROS generation. Reversible deactivation of mitochondrial complex I is an intrinsic mechanism, which provides a fast response of the mitochondrial respiratory chain to oxygen deprivation. However, subsequent re-oxygenation leads to ROS generation due to the rapid burst of respiration. Under normoxic conditions, a high level of NADH can drive forward electron flow with superoxide generation at the flavin mononucleotide moiety located near the NADH binding subunit. During re-oxygenation, reverse electron flow driven by a reduced ubiquinone (ubiquinol) pool and high proton motive force can generate ROS when electrons flow back from ubiquinol to Complex I. CH<sub>4</sub> treatment restricts the forward electron transfer within complex I in control mitochondria while effectively inhibiting RET in post-ischemic mitochondria.

Mitochondrial complex I has two conformations with different catalytic activities: an active state (A) and a deactivated state (D), which are present in A/D equilibrium in a ratio of 9:7 under physiological conditions [64]. The A/D transition occurs during ischemia/anoxia, as an intrinsic mechanism which produces a rapid response of the mitochondrial ETC to oxygen deprivation [65]. Modulating factors of the A/D transition include the availability of oxygen, the reduced NAD pool in the matrix, the temperature and the pH. The physiological role of the accumulation of the D-form in anoxia is most probably to protect mitochondria from ROS generation due to the rapid burst of respiration following re-oxygenation [59, 66]. The transient preservation of complex I in the D-form was implemented as a successful strategy against reperfusion injury in the post-ischemic brain and heart [10, 62, 66]. Although the

entire NAD pool is reduced under ischemic/anoxic conditions, the nucleotide at the flavin site could be rapidly reduced by the RET directly from ubiquinol at the beginning of re-oxygenation (Fig 12).



**Fig 12. Transition of complex I between its activated (A) and deactivated (D) state.** Forward flow of electrons occurs during the (A) state, which represents the physiological functioning of mitochondria. In the presence of complex I inhibitor rotenone, reverse electron flow can be triggered (upper right picture). During hypoxia complex I stays in its (D) state, while CH<sub>4</sub> can maintain this deactivated conformation during the re-oxygenation period, inhibiting the formation of RET, which is the main source of ROS.

However, the D-form of the enzyme is unable to catalyze the RET, and therefore deactivation may act as a protective valve by preventing reduction of the enzyme from downstream. Both the D-form of complex I and the rotenone-inhibited enzyme have restricted access to the quinone-binding pocket [12]. The functional outcome of this is, on the one hand, similar to the blockade of forward electron transfer within the A-form by a molecule of rotenone-like inhibitor bound at the quinone site. On the other hand, the RET occurring in the D-form of the enzyme can also be restricted, thereby abolishing the ROS formation [58, 64].



## 6. SUMMARY OF NEW FINDINGS

- <sup>1</sup> Our study has demonstrated that CH<sub>4</sub> enrichment of preservation solution during cold ischemia results in increased graft protection in isogenic rat heart transplantation.
- <sup>2</sup> The CH<sub>4</sub>-containing CS effectively reduces the degree of oxido-reductive stress in myocardial samples as evidenced by maintained GSH/GSSG ratio and lower NOx level in the reperfused myocardium together with decreased tissue MPO and XOR activity.
- The underlying mechanism is <sup>30</sup> related to the effect of CH<sub>4</sub> on ER stress and <sup>22</sup> the structural and functional integrity of cardiac mitochondria.
- The interaction between the mitochondria and ER involves the changes in extramitochondrial Ca<sup>2+</sup> fluxes.
- The Ca<sup>2+</sup>-induced mitochondrial membrane potential changes are decreased by anoxia, however, CH<sub>4</sub> can restore the magnitude of hyperpolarisation.
- The anti-oxidative effects of CH<sub>4</sub> are related to the reduced mitochondrial <sup>2</sup> ROS generation via a partial blockade of electron transport in complex I.

## 7. ACKNOWLEDGMENTS

I am thankful to Dr. Petra Hartmann, who initiated my scientific career and helped me acquire experimental skills, scientific thinking and conceptualization while granted me unlimited daily assistance in performing the studies, writing publications and holding scientific lectures in several conferences. I am also grateful to Prof. Mihály Boros to provide me the opportunity to carry out my scientific work in the Institute of Surgical Research under his valuable scientific guidance and with his help. I am still indebted to Bálint Baráth and Ágnes Lilla Szilágyi Ph.D., who helped me acquire basic experimental skills, and helped me in the start of the majority of these experiments. I am also grateful to Dr. Kálmán Benke, whose practice in heart transplantation was indispensable to carry out Study I. I would also like to thank the TDK students (non-exhaustively: Anett Roxána Márton, and Petra Varga) for their conscientious and enthusiastic work. I also thank Nikolett Zádoriné Beretka and Csilla Mester for providing a stable background for the experiments and the biochemical assays.

## 8. FUNDING STATEMENT

Hungarian Academy of Sciences János Bolyai Research Scholarship, grant BO/00605/21/5 (PH). National Research, Development, and Innovation Office (NFKIH) grants K12023 (MB) and FK138839 (PH).

## 9. REFERENCES

1. Hearse DJ, Bolli R. Reperfusion-induced injury manifestations, mechanisms, and clinical relevance. Trends in cardiovascular medicine. 1991;1(6):233-40. doi: 10.1016/1050-1738(91)90027-C. PubMed PMID: 21239301.
2. Jia JJ, Li JH, Jiang L, Lin BY, Wang L, Su R, et al. Liver protection strategies in liver transplantation. Hepatobiliary & pancreatic diseases international : HBPD INT. 2015;14(1):34-42. doi: 10.1016/s1499-3872(15)60332-0. PubMed PMID: 25655288.
3. Brisson H, Arbelot C, Monsel A, Parisot C, Girard M, Savier E, et al. Impact of graft preservation solutions for liver transplantation on early cytokine release and postoperative organ dysfunctions. A pilot study. Clinics and research in hepatology and gastroenterology. 2017;41(5):564-74. doi: 10.1016/j.clinre.2016.12.011. PubMed PMID: 28330599.
4. Horvath T, Jasz DK, Barath B, Poles MZ, Boros M, Hartmann P. Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation. International journal of molecular sciences. 2021;22(6). doi: 10.3390/ijms22062816. PubMed PMID: 33802177; PubMed Central PMCID: PMC7998211.
5. Striffler G, Tuboly E, Szel E, Kaszonyi E, Cao C, Kaszaki J, et al. Inhaled Methane

Limits the Mitochondrial Electron Transport Chain Dysfunction during Experimental Liver Ischemia-Reperfusion Injury. *PLoS One*. 2016;11(1):e0146363. doi: 10.1371/journal.pone.0146363. PubMed PMID: 26741361; PubMed Central PMCID: PMC4720186.

6. Benke K, Jasz DK, Szilagyi AL, Barath B, Tuboly E, Marton AR, et al. Methane supplementation improves graft function in experimental heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2021;40(3):183-92. doi: 10.1016/j.healun.2020.11.003. PubMed PMID: 33277170.

7. Martins RM, Teodoro JS, Furtado E, Oliveira RC, Tralhao JG, Rolo AP, et al. Mild hypothermia during the reperfusion phase protects mitochondrial bioenergetics against ischemia-reperfusion injury in an animal model of ex-vivo liver transplantation-an experimental study. *International journal of medical sciences*. 2019;16(9):1304-12. doi: 10.7150/ijms.34617. PubMed PMID: 31588197; PubMed Central PMCID: PMC6775262.

8. Chouchani ET, Pell VR, James AM, Work LM, Saeb-Parsy K, Frezza C, et al. A Unifying Mechanism for Mitochondrial Superoxide Production during Ischemia-Reperfusion Injury. *Cell metabolism*. 2016;23(2):254-63. doi: 10.1016/j.cmet.2015.12.009. PubMed PMID: 26777689.

9. Ernst L, Steinfeld B, Barayeu U, Klintzsch T, Kurth M, Grimm D, et al. Methane formation driven by reactive oxygen species across all living organisms. *Nature*. 2022;603(7901):482-7. doi: 10.1038/s41586-022-04511-9. PubMed PMID: 35264795.

10. Korge P, John SA, Calmettes G, Weiss JN. Reactive oxygen species production induced by pore opening in cardiac mitochondria: The role of complex II. *J Biol Chem*. 2017;292(24):9896-905. doi: 10.1074/jbc.M116.768325. PubMed PMID: 28450394; PubMed Central PMCID: PMC5473242.

11. Song AT, Avelino-Silva VI, Pecora RA, Pugliese V, D'Albuquerque LA, Abdala E. Liver transplantation: fifty years of experience. *World journal of gastroenterology*. 2014;20(18):5363-74. doi: 10.3748/wjg.v20.i18.5363. PubMed PMID: 24833866; PubMed Central PMCID: PMC4017051.

12. Braithwaite SA, van der Kaaij NP. New Techniques for Optimization of Donor Lungs/Hearts. *Anesthesiology clinics*. 2019;37(4):639-60. doi: 10.1016/j.anclin.2019.08.010. PubMed PMID: 31677683.

13. Ardehali A, Esmailian F, Deng M, Soltesz E, Hsieh E, Naka Y, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. *Lancet*. 2015;385(9987):2577-84. doi: 10.1016/S0140-6736(15)60261-6. PubMed PMID: 25888086.

14. Li Y, Guo S, Liu G, Yuan Y, Wang W, Zheng Z, et al. Three Preservation Solutions for Cold Storage of Heart Allografts: A Systematic Review and Meta-Analysis. *Artificial organs*. 2016;40(5):489-96. doi: 10.1111/aor.12585. PubMed PMID: 26526678.

15. Dougherty RW, Riley JL, Baetz AL, Cook HM, Coburn KS. Physiologic studies of experimentally grain-engorged cattle and sheep. *American journal of veterinary research*. 1975;36(6):833-5. PubMed PMID: 238439.

16. Carlisle SM, Burchart PA, McCauley C, Surette RA. Biokinetics of inhaled radioactive methane in rats: a pilot study. *Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine*. 2005;62(6):847-60. doi: 10.1016/j.apradiso.2005.01.010. PubMed PMID: 15799862.

17. Keppler F, Hamilton JT, Brass M, Rockmann T. Methane emissions from terrestrial plants under aerobic conditions. *Nature*. 2006;439(7073):187-91. doi: 10.1038/nature04420. PubMed PMID: 16407949.

18. Lenhart K, Bunge M, Ratering S, Neu TR, Schuttmann I, Greule M, et al. Evidence

- for methane production by saprotrophic fungi. *Nature communications*. 2012;3:1046. doi: 10.1038/ncomms2049. PubMed PMID: 22948828.
19. Althoff F, Benzing K, Comba P, McRoberts C, Boyd DR, Greiner S, et al. Abiotic methanogenesis from organosulphur compounds under ambient conditions. *Nature communications*. 2014;5:4205. doi: 10.1038/ncomms5205. PubMed PMID: 24957135.
  20. Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen JH, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *American journal of physiology Gastrointestinal and liver physiology*. 2006;290(6):G1089-95. doi: 10.1152/ajpgi.00574.2004. PubMed PMID: 16293652.
  21. Mathur R, Mundi MS, Chua KS, Lorentz PA, Barlow GM, Lin E, et al. Intestinal methane production is associated with decreased weight loss following bariatric surgery. *Obes Res Clin Pract*. 2016;10(6):728-33. doi: 10.1016/j.orcp.2016.06.006. PubMed PMID: 27380731.
  22. Boros M, Ghyczy M, Erces D, Varga G, Tokes T, Kupai K, et al. The anti-inflammatory effects of methane. *Critical care medicine*. 2012;40(4):1269-78. doi: 10.1097/CCM.0b013e31823dae05. PubMed PMID: 22336723.
  23. Poles MZ, Bodi N, Bagyanszki M, Fekete E, Meszaros AT, Varga G, et al. Reduction of nitrosative stress by methane: Neuroprotection through xanthine oxidoreductase inhibition in a rat model of mesenteric ischemia-reperfusion. *Free Radic Biol Med*. 2018;120:160-9. doi: 10.1016/j.freeradbiomed.2018.03.024. PubMed PMID: 29550332.
  24. Boros M, Tuboly E, Meszaros A, Amann A. The role of methane in mammalian physiology-is it a gasotransmitter? *Journal of breath research*. 2015;9(1):014001. doi: 10.1088/1752-7155/9/1/014001. PubMed PMID: 25624411.
  25. Varga G, Erces D, Tuboly E, Kaszaki J, Ghyczy M, Boros M. [Characterization of the antiinflammatory properties of methane inhalation during ischaemia-reperfusion]. *Magyar sebeszet*. 2012;65(4):205-11. doi: 10.1556/MaSeb.65.2012.4.6. PubMed PMID: 22940389.
  26. Tong Y, Dong Y, Feng Y, Li Z, Jia Y, Zhang X, et al. Methane-Rich Saline: A Potential Resuscitation Fluid for Hemorrhagic Shock. *Oxidative medicine and cellular longevity*. 2019;2019:4929107. doi: 10.1155/2019/4929107. PubMed PMID: 31885797; PubMed Central PMCID: PMC6899305 this article.
  27. Martins RM, Pinto Rolo A, Soeiro Teodoro J, Furtado E, Caetano Oliveira R, Tralhao JG, et al. Addition of Berberine to Preservation Solution in an Animal Model of Ex Vivo Liver Transplant Preserves Mitochondrial Function and Bioenergetics from the Damage Induced by Ischemia/Reperfusion. *International journal of molecular sciences*. 2018;19(1). doi: 10.3390/ijms19010284. PubMed PMID: 29351246; PubMed Central PMCID: PMC5796230.
  28. Meszaros AT, Szilagyi AL, Juhasz L, Tuboly E, Erces D, Varga G, et al. Mitochondria As Sources and Targets of Methane. *Front Med (Lausanne)*. 2017;4:195. doi: 10.3389/fmed.2017.00195. PubMed PMID: 29181377; PubMed Central PMCID: PMC5693848.
  29. Chen O, Ye Z, Cao Z, Manaenko A, Ning K, Zhai X, et al. Methane attenuates myocardial ischemia injury in rats through anti-oxidative, anti-apoptotic and anti-inflammatory actions. *Free Radic Biol Med*. 2016;90:1-11. doi: 10.1016/j.freeradbiomed.2015.11.017. PubMed PMID: 26585905.
  30. Song K, Zhang M, Hu J, Liu Y, Liu Y, Wang Y, et al. Methane-rich saline attenuates ischemia/reperfusion injury of abdominal skin flaps in rats via regulating apoptosis level. *BMC surgery*. 2015;15:92. doi: 10.1186/s12893-015-0075-4. PubMed PMID: 26228913; PubMed Central PMCID: PMC4520019.
  31. Wang L, Yao Y, He R, Meng Y, Li N, Zhang D, et al. Methane ameliorates spinal cord ischemia-reperfusion injury in rats: Antioxidant, anti-inflammatory and anti-apoptotic

- activity mediated by Nrf2 activation. *Free Radic Biol Med*. 2017;103:69-86. doi: 10.1016/j.freeradbiomed.2016.12.014. PubMed PMID: 28007572.
32. Rakhit RD, Mojet MH, Marber MS, Duchon MR. Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reoxygenation in isolated neonatal cardiomyocytes. *Circulation*. 2001;103(21):2617-23. doi: 10.1161/01.cir.103.21.2617. PubMed PMID: 11382733.
  33. Szilagyí AL, Matrai P, Hegyi P, Tuboly E, Pecz D, Garami A, et al. Compared efficacy of preservation solutions on the outcome of liver transplantation: Meta-analysis. *World journal of gastroenterology*. 2018;24(16):1812-24. doi: 10.3748/wjg.v24.i16.1812. PubMed PMID: 29713134; PubMed Central PMCID: PMC5922999.
  34. Fan DF, Hu HJ, Sun Q, Lv Y, Ye ZH, Sun XJ, et al. Neuroprotective effects of exogenous methane in a rat model of acute carbon monoxide poisoning. *Brain research*. 2016;1633:62-72. doi: 10.1016/j.brainres.2015.12.019. PubMed PMID: 26711852.
  35. Brenner C, Kroemer G. Apoptosis. Mitochondria--the death signal integrators. *Science*. 2000;289(5482):1150-1. doi: 10.1126/science.289.5482.1150. PubMed PMID: 10970229.
  36. Ye Z, Chen O, Zhang R, Nakao A, Fan D, Zhang T, et al. Methane Attenuates Hepatic Ischemia/Reperfusion Injury in Rats Through Antiapoptotic, Anti-Inflammatory, and Antioxidative Actions. *Shock*. 2015;44(2):181-7. doi: 10.1097/SHK.0000000000000385. PubMed PMID: 26009821.
  37. Tuboly E, Szabo A, Eros G, Mohacsi A, Szabo G, Tengolics R, et al. Determination of endogenous methane formation by photoacoustic spectroscopy. *Journal of breath research*. 2013;7(4):046004. doi: 10.1088/1752-7155/7/4/046004. PubMed PMID: 24185326.
  38. Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. *Free Radic Biol Med*. 1989;6(6):607-15. doi: 10.1016/0891-5849(89)90068-3. PubMed PMID: 2753392.
  39. Kuebler WM, Abels C, Schuerer L, Goetz AE. Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. *Int J Microcirc Clin Exp*. 1996;16(2):89-97. doi: 10.1159/000179155. PubMed PMID: 8737712.
  40. Purnak T, Beyazit Y, Ibis M, Koklu S, Efe C, Ozaslan E, et al. The involvement of nitric oxide in the physiopathology of hepatportal sclerosis. *Clinical biochemistry*. 2012;45(16-17):1450-4. doi: 10.1016/j.clinbiochem.2012.07.091. PubMed PMID: 22820432.
  41. Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. *The American journal of pathology*. 2004;164(1):1-7. doi: 10.1016/S0002-9440(10)63089-1. PubMed PMID: 14695312; PubMed Central PMCID: PMC1602240.
  42. Yeh T, Jr., Hanan SA, Johnson DE, Rebeyka IM, Abd-Elfattah AS, Lee KF, et al. Superior myocardial preservation with modified UW solution after prolonged ischemia in the rat heart. *The Annals of thoracic surgery*. 1990;49(6):932-9. doi: 10.1016/0003-4975(90)90869-8. PubMed PMID: 2369191.
  43. Kuznetsov AV, Strobl D, Ruttman E, Konigsrainer A, Margreiter R, Gnaiger E. Evaluation of mitochondrial respiratory function in small biopsies of liver. *Analytical biochemistry*. 2002;305(2):186-94. doi: 10.1006/abio.2002.5658. PubMed PMID: 12054447.
  44. Nakao A, Kaczorowski DJ, Wang Y, Cardinal JS, Buchholz BM, Sugimoto R, et al. Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2010;29(5):544-53. doi: 10.1016/j.healun.2009.10.011. PubMed PMID: 20036162.

45. Srinivasan PK, Yagi S, Doorschodt B, Nagai K, Afify M, Uemoto S, et al. Impact of venous systemic oxygen persufflation supplemented with nitric oxide gas on cold-stored, warm ischemia-damaged experimental liver grafts. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2012;18(2):219-25. doi: 10.1002/lt.22442. PubMed PMID: 21987402.
46. Poles MZ, Juhasz L, Boros M. Methane and Inflammation - A Review (Fight Fire with Fire). *Intensive care medicine experimental*. 2019;7(1):68. doi: 10.1186/s40635-019-0278-6. PubMed PMID: 31807906; PubMed Central PMCID: PMC6895343.
47. Boros M, Keppler F. Methane Production and Bioactivity-A Link to Oxido-Reductive Stress. *Frontiers in physiology*. 2019;10:1244. doi: 10.3389/fphys.2019.01244. PubMed PMID: 31611816; PubMed Central PMCID: PMC6776796.
48. Delbrel E, Soumare A, Naguez A, Label R, Bernard O, Bruhat A, et al. HIF-1alpha triggers ER stress and CHOP-mediated apoptosis in alveolar epithelial cells, a key event in pulmonary fibrosis. *Sci Rep*. 2018;8(1):17939. Epub 20181218. doi: 10.1038/s41598-018-36063-2. PubMed PMID: 30560874; PubMed Central PMCID: PMC6299072.
49. Lopez-Hernandez B, Cena V, Posadas I. The endoplasmic reticulum stress and the HIF-1 signalling pathways are involved in the neuronal damage caused by chemical hypoxia. *Br J Pharmacol*. 2015;172(11):2838-51. doi: 10.1111/bph.13095. PubMed PMID: 25625917; PubMed Central PMCID: PMC4439879.
50. Rizzuto R, Marchi S, Bonora M, Aguiari P, Bononi A, De Stefani D, et al. Ca(2+) transfer from the ER to mitochondria: when, how and why. *Biochim Biophys Acta*. 2009;1787(11):1342-51. doi: 10.1016/j.bbabo.2009.03.015. PubMed PMID: 19341702; PubMed Central PMCID: PMC2730423.
51. Yang D, Gao L, Wang T, Qiao Z, Liang Y, Zhang P. Hypoxia triggers endothelial endoplasmic reticulum stress and apoptosis via induction of VLDL receptor. *FEBS Lett*. 2014;588(23):4448-56. doi: 10.1016/j.febslet.2014.09.046. PubMed PMID: 25448985.
52. Huang D, Yan ML, Chen KK, Sun R, Dong ZF, Wu PL, et al. Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2018;46(1):9-22. doi: 10.1159/000488404. PubMed PMID: 29566363.
53. Yang K, Chen Z, Gao J, Shi W, Li L, Jiang S, et al. The Key Roles of GSK-3beta in Regulating Mitochondrial Activity. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2017;44(4):1445-59. doi: 10.1159/000485580. PubMed PMID: 29190615.
54. Jasz DK, Szilagyi AL, Tuboly E, Barath B, Marton AR, Varga P, et al. Reduction in hypoxia-reoxygenation-induced myocardial mitochondrial damage with exogenous methane. *Journal of cellular and molecular medicine*. 2021;25(11):5113-23. doi: 10.1111/jcmm.16498. PubMed PMID: 33942485; PubMed Central PMCID: PMC8178286.
55. Chouchani ET, Methner C, Nadochiy SM, Logan A, Pell VR, Ding S, et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. *Nature medicine*. 2013;19(6):753-9. doi: 10.1038/nm.3212. PubMed PMID: 23708290; PubMed Central PMCID: PMC4019998.
56. Xu A, Szczepanek K, Maceyka MW, Ross T, Bowler E, Hu Y, et al. Transient complex I inhibition at the onset of reperfusion by extracellular acidification decreases cardiac injury. *American journal of physiology Cell physiology*. 2014;306(12):C1142-53. doi: 10.1152/ajpcell.00241.2013. PubMed PMID: 24696146; PubMed Central PMCID: PMC4059999.



57. Teixeira G, Abrial M, Portier K, Chiari P, Couture-Lepetit E, Tourneur Y, et al. Synergistic protective effect of cyclosporin A and rotenone against hypoxia-reoxygenation in cardiomyocytes. *Journal of molecular and cellular cardiology*. 2013;56:55-62. doi: 10.1016/j.yjmcc.2012.11.023. PubMed PMID: 23238221.
58. Treberg JR, Quinlan CL, Brand MD. Evidence for two sites of superoxide production by mitochondrial NADH-ubiquinone oxidoreductase (complex I). *J Biol Chem*. 2011;286(31):27103-10. doi: 10.1074/jbc.M111.252502. PubMed PMID: 21659507; PubMed Central PMCID: PMC3149303.
59. Ringe B, Braun F, Moritz M, Zeldin G, Soriano H, Meyers W. Safety and efficacy of living donor liver preservation with HTK solution. *Transplantation proceedings*. 2005;37(1):316-9. doi: 10.1016/j.transproceed.2004.12.009. PubMed PMID: 15808629.
60. Meng Y, Jiang Z, Li N, Zhao Z, Cheng T, Yao Y, et al. Protective Effects of Methane-Rich Saline on Renal Ischemic-Reperfusion Injury in a Mouse Model. *Medical science monitor : international medical journal of experimental and clinical research*. 2018;24:7794-801. doi: 10.12659/MSM.911156. PubMed PMID: 30379804; PubMed Central PMCID: PMC6223098.
61. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature*. 2014;515(7527):431-5. doi: 10.1038/nature13909. PubMed PMID: 25383517; PubMed Central PMCID: PMC4255242.
62. Votyakova TV, Reynolds JJ. DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. *J Neurochem*. 2001;79(2):266-77. doi: 10.1046/j.1471-4159.2001.00548.x. PubMed PMID: 11677254.
63. Gorenkova N, Robinson E, Grieve DJ, Galkin A. Conformational change of mitochondrial complex I increases ROS sensitivity during ischemia. *Antioxidants & redox signaling*. 2013;19(13):1459-68. doi: 10.1089/ars.2012.4698. PubMed PMID: 23419200; PubMed Central PMCID: PMC3797456.
64. Babot M, Birch A, Labarbuta P, Galkin A. Characterisation of the active/de-active transition of mitochondrial complex I. *Biochim Biophys Acta*. 2014;1837(7):1083-92. doi: 10.1016/j.bbabo.2014.02.018. PubMed PMID: 24569053; PubMed Central PMCID: PMC4331042.
65. Jain IH, Zazzaron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, et al. Hypoxia as a therapy for mitochondrial disease. *Science*. 2016;352(6281):54-61. doi: 10.1126/science.aad9642. PubMed PMID: 26917594; PubMed Central PMCID: PMC4860742.
66. Zickermann V, Wirth C, Nasiri H, Siegmund K, Schwalbe H, Hunte C, et al. Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. *Science*. 2015;347(6217):44-9. doi: 10.1126/science.1259859. PubMed PMID: 25554780.

# THE PROTECTIVE ROLE OF METHANE IN MITOCHONDRIAL AND METABOLIC PATHWAYS OF ISCHEMIA/REPERFUSION-INDUCED CARDIAC DAMAGE

ORIGINALITY REPORT

61%

SIMILARITY INDEX

## PRIMARY SOURCES

- |   |  |                  |
|---|--|------------------|
| 1 | Kálmán Benke, Dávid Kurszán Jász, Ágnes Lilla Szilágyi, Bálint Baráth et al. "METHANE SUPPLEMENTATION IMPROVES GRAFT FUNCTION IN EXPERIMENTAL HEART TRANSPLANTATION", The Journal of Heart and Lung Transplantation, 2020<br><small>Crossref</small> | 2295 words — 23% |
| 2 | <a href="http://publicatio.bibl.u-szeged.hu">publicatio.bibl.u-szeged.hu</a><br><small>Internet</small>  | 1625 words — 16% |
| 3 | <a href="http://doktori.bibl.u-szeged.hu">doktori.bibl.u-szeged.hu</a><br><small>Internet</small>  | 1064 words — 11% |
| 4 | <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a><br><small>Internet</small>  | 315 words — 3%   |
| 5 | <a href="http://www.nature.com">www.nature.com</a><br><small>Internet</small>  | 204 words — 2%   |
| 6 | <a href="http://www.mdpi.com">www.mdpi.com</a><br><small>Internet</small>  | 104 words — 1%   |
| 7 | <a href="http://journals.plos.org">journals.plos.org</a><br><small>Internet</small>  | 73 words — 1%    |

8	Internet	71 words — 1%
9	ir.lib.uwo.ca Internet	34 words — < 1%
10	wjgnet.com Internet	32 words — < 1%
11	essay.utwente.nl Internet	25 words — < 1%
12	real.mtak.hu Internet	20 words — < 1%
13	phd.szote.u-szeged.hu Internet	17 words — < 1%
14	www.zora.uzh.ch Internet	16 words — < 1%
15	Melanie Y. White. "Proteomics of ischemia and reperfusion injuries in rabbit myocardium with and without intervention by an oxygen-free radical scavenger", PROTEOMICS, 12/2006 Crossref	14 words — < 1%
16	"Bcl-2 Family Members Regulate Anoxia-Induced Cell Death", Antioxidants & Redox Signaling, 09/2007 Crossref	13 words — < 1%
17	"Technological Advances in Organ Transplantation", Springer Science and Business Media LLC, 2017 Crossref	13 words — < 1%

18 Joohyun Kim, Michael A. Zimmerman, Johnny C. Hong. "Emerging Innovations in Liver Preservation and Resuscitation", Transplantation Proceedings, 2018

Crossref

10 words — < 1%

19 Péter Hegedűs, Shiliang Li, Sevil Korkmaz-Icöz, Tamás Radovits et al. "Dimethyloxalylglycine treatment of brain-dead donor rats improves both donor and graft left ventricular function after heart transplantation", The Journal of Heart and Lung Transplantation, 2016

Crossref

10 words — < 1%

20 S Loganathan, S Korkmaz, E Barnucz, K Hirschberg, B Seidel, T Radovits, S Li, A Weymann, M Karck, G Szabó. "Protection by cinaciguat, a soluble guanylate cyclase activator against ischemia/reperfusion-induced injury in the transplanted rat heart", The Thoracic and Cardiovascular Surgeon, 2011

Crossref

10 words — < 1%

21 ifcardio.org

Internet

10 words — < 1%

22 "Pharmacology of Mitochondria", Springer Science and Business Media LLC, 2017

Crossref

9 words — < 1%

23 Péter Palágyi. "Monitoring gastrointestinal mucosal perfusion by tissue capnometry in anaesthesiology and intensive therapy", University of Szeged, 2016

Crossref Posted Content

9 words — < 1%

24 bioblast.at

Internet

9 words — < 1%

- 
- 25 [www.frontiersin.org](http://www.frontiersin.org) 9 words — < 1%  
Internet
- 
- 26 [www.imrpress.com](http://www.imrpress.com) 9 words — < 1%  
Internet
- 
- 27 [www.science.gov](http://www.science.gov) 9 words — < 1%  
Internet
- 
- 28 Kenji Okuda, Masatoshi Murai, Shunsuke Aburaya, Wataru Aoki, Hideto Miyoshi. "Reduction of Synthetic Ubiquinone QT Catalyzed by Bovine Mitochondrial Complex I Is Decoupled from Proton Translocation", Biochemistry, 2016 8 words — < 1%  
Crossref
- 
- 29 Liping Wang, Ying Yao, Rong He, Yan Meng et al. "Methane ameliorates spinal cord ischemia-reperfusion injury in rats: Antioxidant, anti-inflammatory and anti-apoptotic activity mediated by Nrf2 activation", Free Radical Biology and Medicine, 2017 8 words — < 1%  
Crossref
- 
- 30 [downloads.hindawi.com](http://downloads.hindawi.com) 8 words — < 1%  
Internet
- 
- 31 Dénes Garab. "Local and remote microcirculatory effects of transient ischemia of the lower extremities in rats", University of Szeged, 2014 7 words — < 1%  
Crossref Posted Content
- 
- 32 S. Li, S. Korkmaz-Icöz, T. Radovits, M. Ruppert et al. "Donor Preconditioning After the Onset of Brain Death With Dopamine Derivate -Octanoyl Dopamine Improves Early Posttransplant Graft Function in the Rat ", American Journal of Transplantation, 2017 7 words — < 1%  
Crossref

---

33

Péter Jávör, Attila Mácsai, Edina Butt, Bálint Baráth  
et al. "Mitochondrial Dysfunction Affects the  
Synovium of Patients with Rheumatoid Arthritis and  
Osteoarthritis Differently", International Journal of Molecular  
Sciences, 2022

Crossref

6 words — < 1%

---

EXCLUDE QUOTES OFF  
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES OFF  
EXCLUDE MATCHES OFF